Periocular sebaceous carcinoma (PSC) is a rare but aggressive neoplasm that tends to clinically and histopathologically mimic other conditions. PSC can be challenging to diagnose using histomorphology alone given its overlap with 2 more common tumors that occur in this area (basal cell carcinoma [BCC] and squamous cell carcinoma [SCC]). Use of immunohistochemistry can help resolve this differential diagnosis.
Methods
A review of the literature was performed, focusing on the epidemiology, morphology, and immunohistochemical features of PSC.
Results
The most useful immunostains in the differential diagnosis of PSC are epithelial membrane antigen, Ber-Ep4, androgen receptor (AR), and adipophilin. To discern PSC from BCC, one should use EMA, Ber-Ep4, AR, and adipophilin, whereas discerning PSC from SCC can be achieved by evaluating AR and adipophilin. In addition, p53 and ERBB2 (formally known as HER2/neu) are other potentially useful immunohistochemical markers for the differential diagnosis of PSC.
Conclusions
Use of new immunohistochemical techniques, as well as the elucidation of molecular alterations, such as the presence of ERBB2 amplification, will advance our understanding of PSC.
References
1.
AndersonH.L., JosephA.K.A pilot feasibility study of a rare skin tumor database.Dermatol Surg.2007; 33(6): 693–696.
2.
KylloR.L., BradyK.L., HurstE.A.Sebaceous carcinoma: review of the literature.Dermatol Surg.2015; 41(1): 1–15.
3.
DasguptaT., WilsonL.D., YuJ.B.A retrospective review of 1349 cases of sebaceous carcinoma.Cancer.2009; 115(1): 158–165.
4.
ShieldsJ.A., DemirciH., MarrB.P.Sebaceous carcinoma of the eyelids: personal experience with 60 cases.Ophthalmology.2004; 111(12): 2151–2157.
5.
ShieldsJ.A., DemirciH., MarrB.P.Sebaceous carcinoma of the ocular region: a review.Surv Ophthalmol.2005; 50(2): 103–122.
6.
ShieldsJ.A., ShieldsC.L.Sebaceous adenocarcinoma of the eyelid.Int Ophthalmol Clin.2009; 49(4): 45–61.
7.
JakobiecF.A., MendozaP.R.Eyelid sebaceous carcinoma: clinicopathologic and multiparametric immunohistochemical analysis that includes adipophilin.Am J Ophthalmol.2014; 157(1): 186–208.e182.
8.
BuitragoW., JosephA.K.Sebaceous carcinoma: the great masquerader: emgerging concepts in diagnosis and treatment.Dermatol Ther.2008; 21(6): 459–466.
9.
OlderJ.J.Eyelid carcinoma–another one of medicine's imitators.Ophthalmic Surg.1989; 20(1): 73.
10.
BoniukM., ZimmermanL.E.Sebaceous carcinoma of the eyelid, eyebrow, caruncle, and orbit.Trans Am Acad Ophthalmol Otolaryngol.1968; 72(4): 619–642.
11.
RaoN.A., HidayatA.A., McLeanI.W.Sebaceous carcinomas of the ocular adnexa: A clinicopathologic study of 104 cases, with five-year follow-up data.Hum Pathol.1982; 13(2): 113–122.
12.
MuqitM.M., RobertsF., LeeW.R.Improved survival rates in sebaceous carcinoma of the eyelid.Eye (Lond).2004; 18(1): 49–53.
13.
HassaneinA.M.Sebaceous carcinoma and the T-antigen.Semin Cutan Med Surg.2004; 23(1): 62–72.
CabralE.S., CassarinoD.S.Desmoplastic tricholemmoma of the eyelid misdiagnosed as sebaceous carcinoma: a potential diagnostic pitfall.J Cutan Pathol.2007; 34(suppl 1): 22–25.
16.
LeverJ.F., ServatJ.J., Nesi-EloffF.Trichoadenoma of an eyelid in an adult mimicking sebaceous cell carcinoma.Ophthal Plast Reconstr Surg.2012; 28(4): e101–102.
17.
JakobiecF.A., MendozaP.R., ColbyK.A.Clinicopathologic and immunohistochemical studies of conjunctival large cell acanthoma, epidermoid dysplasia, and squamous papilloma.Am J Ophthalmol.2013; 156(4): 830–846.
18.
KhongJ.J., LeibovitchI., SelvaD.Sebaceous gland carcinoma of the eyelid presenting as a conjunctival papilloma.Clin Experiment Ophthalmol.2005; 33(2): 197–198.
19.
StagnerA.M., JakobiecF.A., ChiA.Conjunctival inverted squamous papilloma: a case report with immunohistochemical analysis and review of the literature.Surv Ophthalmol.2015; 60(3): 263–268.
20.
MissottenG.S., de Wolff-RouendaalD., de KeizerR.J.Merkel cell carcinoma of the eyelid review of the literature and report of patients with Merkel cell carcinoma showing spontaneous regression.Ophthalmology.2008; 115(1): 195–201.
21.
SlutskyJ.B., JonesE.C.Periocular cutaneous malignancies: a review of the literature.Dermatol Surg.2012; 38(4): 552–569.
OstlerD.A., PrietoV.G., ReedJ.A.Adipophilin expression in sebaceous tumors and other cutaneous lesions with clear cell histology: an immunohistochemical study of 117 cases.Mod Pathol.2010; 23(4): 567–573.
24.
PlazaJ.A., MackinnonA., CarrilloL.Role of immunohistochemistry in the diagnosis of sebaceous carcinoma: a clinicopathologic and immunohistochemical study.Am J Dermatopathol.2015; 37(11): 809–821.
25.
AnsaiS., AraseS., KawanaS.Immunohistochemical findings of sebaceous carcinoma and sebaceoma: retrieval of cytokeratin expression by a panel of anti-cytokeratin monoclonal antibodies.J Dermatol.2011; 38(10): 951–958.
26.
PaiR.K., WestR.B.MOC-31 exhibits superior reactivity compared with Ber-EP4 in invasive lobular and ductal carcinoma of the breast: a tissue microarray study.Appl Immunohistochem Mol Morphol.2009; 17(3): 202–206.
27.
WinterM.J., NagtegaalI.D., van KriekenJ.H.The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology.Am J Pathol.2003; 163(6): 2139–2148.
SramekB., LisleA., LoyT.Immunohistochemistry in ocular carcinomas.J Cutan Pathol.2008; 35(7): 641–646.
30.
HeylJ., MehreganD.Immunolabeling pattern of cytokeratin 19 expression may distinguish sebaceous tumors from basal cell carcinomas.J Cutan Pathol.2008; 35(1): 40–45.
31.
KanitakisJ., al-RifaiI., FaureM.Thomsen-Friedenreich and its precursor (Tn) antigen expression in normal skin and in benign cutaneous tumours: a marker for sebaceous differentiation.Acta Derm Venereol.1998; 78(3): 173–176.
32.
HassaneinA.M., Al-QuranS.Z., KantorG.R.Thomsen-Friedenreich (T) antigen: a possible tool for differentiating sebaceous carcinoma from its simulators.Appl Immunohistochem Mol Morphol.2001; 9(3): 250–254.
33.
MuthusamyK., HalbertG., RobertsF.Immunohistochemical staining for adipophilin, perilipin and TIP47.J Clin Pathol.2006; 59(11): 1166–1170.
34.
StraubB.K., HerpelE., SingerS.Lipid droplet-associated PAT-proteins show frequent and differential expression in neoplastic steatogenesis.Mod Pathol.2010; 23(3): 480–492.
35.
MeadowsJ.W., PitzerB., BrockmanD.E.Expression and localization of adipophilin and perilipin in human fetal membranes: association with lipid bodies and enzymes involved in prostaglandin synthesis.J Clin Endocrinol Metab.2005; 90(4): 2344–2350.
36.
MarianoF.V., dos SantosH.T., AzaneroW.D.Mammary analogue secretory carcinoma of salivary glands is a lipid-rich tumour, and adipophilin can be valuable in its identification.Histopathology.2013; 63(4): 558–567.
37.
MoritaniS., IchiharaS., HasegawaM.Intracytoplasmic lipid accumulation in apocrine carcinoma of the breast evaluated with adipophilin immunoreactivity: a possible link between apocrine carcinoma and lipidrich carcinoma.Am J Surg Pathol.2011; 35(6): 861–867.
38.
HoffmanA., GhadimiM.P., DemiccoE.G.Localized and metastatic myxoid/round cell liposarcoma: clinical and molecular observations.Cancer.2013; 119(10): 1868–1877.
39.
BoussahmainC., MochelM.C., HoangM.P.Perilipin and adipophilin expression in sebaceous carcinoma and mimics.Hum Pathol.2013; 44(9): 1811–1816.
40.
MilmanT., SchearM.J., EagleR.C.Jr. Diagnostic utility of adipophilin immunostain in periocular carcinomas.Ophthalmology.2014; 121(4): 964–971.
41.
Ruizeveld de WinterJ.A., TrapmanJ., VermeyM.Androgen receptor expression in human tissues: an immunohistochemical study.J Histochem Cytochem.1991; 39(7): 927–936.
42.
Asadi-AmoliF., KhoshnevisF., HaeriH.Comparative examination of androgen receptor reactivity for differential diagnosis of sebaceous carcinoma from squamous cell and basal cell carcinoma.Am J Clin Pathol.2010; 134(1): 22–26.
43.
KiyosakiK., NakadaC., HijiyaN.Analysis of p53 mutations and the expression of p53 and p21WAF1/CIP1 protein in 15 cases of sebaceous carcinoma of the eyelid.Invest Ophthalmol Vis Sci.2010; 51(1): 7–11.
44.
BaumullerS., HerwigM.C., MangoldE.Sebaceous gland carcinoma of the eyelid masquerading as a cutaneous horn in Li–Fraumeni syndrome.Br J Ophthalmol.2011; 95(10): 1470, 1478.
45.
ShalinS.C., SakharpeA., LyleS.p53 staining correlates with tumor type and location in sebaceous neoplasms.Am J Dermatopathol.2012; 34(2): 129–135; quiz 136-128.
46.
BarrettT.L., SmithK.J., HodgeJ.J.Immunohistochemical nuclear staining for p53, PCNA, and Ki-67 in different histologic variants of basal cell carcinoma.J Am Acad Dermatol.1997; 37(3 Pt 1): 430–437.
47.
AthanassiadouA.M., LazarisA.C., PatsourisE.Significance of cyclooxygenase 2, EZH-2 polycomb group and p53 expression in actinic keratosis and squamous cell carcinomas of the skin.Am J Dermatopathol.2013; 35(4): 425–431.
48.
BoennelyckeM., ThomsenB.M., HolckS.Sebaceous neoplasms and the immunoprofile of mismatch-repair proteins as a screening target for syndromic cases.Pathol Res Pract.2015; 211(1): 78–82.
49.
MathiakM., RuttenA., MangoldE.Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test.Am J Surg Pathol.2002; 26(3): 338–343.
50.
PlocharczykE.F., FrankelW.L., HampelH.Mismatch repair protein deficiency is common in sebaceous neoplasms and suggests the importance of screening for Lynch syndrome.Am J Dermatopathol.2013; 35(2): 191–195.
51.
Rajan KdA., BurrisC., IliffN.DNA mismatch repair defects and microsatellite instability status in periocular sebaceous carcinoma.Am J Ophthalmol.2014; 157(3): 640–647.e641-642.
52.
LiauJ.Y., LiaoS.L., HsiaoC.H.Hypermethylation of the CDK-N2A gene promoter is a frequent epigenetic change in periocular sebaceous carcinoma and is associated with younger patient age.Hum Pathol.2014; 45(3): 533–539.
53.
JaganL., ZoroquiainP., Bravo-FilhoV.Sebaceous adenomas of the eyelid and Muir-Torre Syndrome.Br J Ophthalmol.2015; 99(7): 909–913.
54.
KwonM.J., ShinH.S., NamE.S.Comparison of HER2 gene amplification and KRAS alteration in eyelid sebaceous carcinomas with that in other eyelid tumors.Pathol Res Pract.2015; 211(5): 349–355.
55.
JayarajP., SenS., SharmaA.Epigenetic inactivation of the E-cadherin gene in eyelid sebaceous gland carcinoma.Br J Dermatol.2012; 167(3): 583–590.
56.
LiL., ZhangZ., LiB.E-cadherin and beta-catenin expression in sebaceous eyelid adenocarcinomas.Graefes Arch Clin Exp Ophthalmol.2011; 249(12): 1867–1873.
57.
BhardwajM., SenS., SharmaA.ZEB2/SIP1 as novel prognostic indicator in eyelid sebaceous gland carcinoma.Hum Pathol.2015.
58.
ChilesM.C., AiL., ZuoC.E-cadherin promoter hypermethylation in preneoplastic and neoplastic skin lesions.Mod Pathol.2003; 16(10): 1014–1018.
PizarroA.E-cadherin expression is frequently reduced in infiltrative basal cell carcinoma.J Dermatol.2000; 27(12): 804–805.
61.
PapadavidE., PignatelliM., ZakynthinosS.Abnormal immunoreactivity of the E-cadherin/catenin (alpha-, beta-, and gamma-) complex in premalignant and malignant non-melanocytic skin tumours.J Pathol.2002; 196(2): 154–162.
62.
PapanikolaouS., BravouV., GyftopoulosK.ILK expression in human basal cell carcinoma correlates with epithelial-mesenchymal transition markers and tumour invasion.Histopathology.2010; 56(6): 799–809.
63.
KosekiS., AokiT., AnsaiS.An immunohistochemical study of E-cadherin expression in human squamous cell carcinoma of the skin: relationship between decreased expression of E-cadherin in the primary lesion and regional lymph node metastasis.J Dermatol.1999; 26(7): 416–422.
